transmission |
7 |
antibodies |
6 |
antibody |
6 |
coronavirus |
6 |
china |
4 |
coronavirus disease 2019 |
4 |
covid‐19 |
4 |
cytokines |
4 |
epidemiology |
4 |
guangdong |
4 |
influenza virus |
4 |
intensive care unit |
4 |
sars-cov-2 |
4 |
sars‐cov‐2 |
4 |
serology |
4 |
seroprevalence |
4 |
avian influenza |
3 |
coronavirus disease 2019 (covid-19) |
3 |
immune response |
3 |
influenza |
3 |
nucleocapsid |
3 |
pandemic influenza a virus |
3 |
pregnancy |
3 |
acute respiratory tract infection |
2 |
adjuvants |
2 |
airborne transmission |
2 |
animal model |
2 |
antibody responses |
2 |
antiviral |
2 |
antiviral resistance |
2 |
avian influenza virus |
2 |
cellular immunity |
2 |
children |
2 |
covid-19 |
2 |
egg-adaptation |
2 |
epidemic |
2 |
ferret |
2 |
ferret model |
2 |
ferrets |
2 |
h10n1 |
2 |
h1n1 |
2 |
h4n2 |
2 |
h7n9 |
2 |
hemagglutinin |
2 |
human adenovirus |
2 |
humoral immunity |
2 |
immune correlate |
2 |
immunity |
2 |
infection |
2 |
influenza a(h3n2) |
2 |
influenza b virus |
2 |
list of abbreviations. |
2 |
low pathogenic avian influenza |
2 |
modeling |
2 |
monocytes |
2 |
mouse |
2 |
mucosal immunity |
2 |
multibasic cleavage site |
2 |
neuraminidase |
2 |
nonstructural protein 1 |
2 |
novel vaccine platforms |
2 |
older adults |
2 |
outbreak |
2 |
pandemic |
2 |
public health |
2 |
quail |
2 |
respiratory virus |
2 |
seroconversion |
2 |
severe acute hepatitis |
2 |
severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
2 |
southern china |
2 |
stalk |
2 |
susceptible-exposed-infectious-removed (seir) |
2 |
t cell |
2 |
tree shrew |
2 |
universal vaccine |
2 |
vaccine |
2 |
vaccine effectiveness |
2 |
vaccines |
2 |
western pacific |
2 |
wild bird |
2 |
zoonosis |
2 |
asia and the pacific |
1 |
autoimmunity |
1 |
b cell |
1 |
biomarker |
1 |
california |
1 |
chemokines |
1 |
colonization |
1 |
control |
1 |
cytokine |
1 |
cytokine. |
1 |
dengue |
1 |
dengue virus |
1 |
dengue viruses |
1 |
discrete event simulation (des) |
1 |
disease burden |
1 |
disease severity |
1 |
duck |
1 |
endoplasmic reticulum |
1 |
evolution |
1 |
fusion glycoprotein |
1 |
gene sequence analysis |
1 |
h10n8 |
1 |
h5 |
1 |
hemagglutination inhibition |
1 |
hemagglutination inhibition antibody |
1 |
heterosubtypic |
1 |
host-pathogen interactions |
1 |
human |
1 |
human infection |
1 |
iceland |
1 |
immunology |
1 |
in vitro model |
1 |
infection control |
1 |
influenza a virus |
1 |
influenza infection attack rate |
1 |
influenza-like illness |
1 |
innate immune response |
1 |
innate immunology |
1 |
ion channels |
1 |
lgg |
1 |
live poultry market |
1 |
localisation |
1 |
lpai |
1 |
m protein |
1 |
membrane fusion |
1 |
monocyte |
1 |
natural influenza virus infection |
1 |
neuraminidase inhibition |
1 |
neuraminidase inhibition antibody |
1 |
neutralizing |
1 |
nosocomial infection |
1 |
nucleic acid detection |
1 |
oligomerisation |
1 |
phylodynamics |
1 |
phylogeny |
1 |
pneumococci |
1 |
prm |
1 |
probiotic |
1 |
process optimization |
1 |
reverse transcription polymerase chain reaction (rt-pcr) |
1 |
risk factors |
1 |
seroepidemiologic cohort |
1 |
subarctic |
1 |
universal influenza vaccine |
1 |
viral |
1 |
wild birds |
1 |
xenopus oocytes |
1 |